Congratulations to PhD candidate Ian Janzen for his work being selected as one of the winners of the BC Cancer 2024 Outstanding Trainee Publication competition, which recognizes excellent research published by students, medical residents, and post-doctoral fellows conducted at BC Cancer.
Most lung cancers are diagnosed at advanced stages, where treatment pathways are determined by target mutations. Patients with lung cancers with a high PD-L1 score currently receive an immunotherapy regimen – however, nearly half of patients do not respond to this approach. Ian’s recent publication develops a predictive risk model using a combination of imaging features (‘radiomics’) from CT scans and clinical descriptors to determine which patients would not benefit from standard immunotherapy treatments.
You can read more here: Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study
Leave a Reply